Stay updated on PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.

Latest updates to the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows an updated revision tag from v3.3.1 to v3.3.2, a minor metadata update with no change to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoChange DetectedPublications are described as automatically filled from PubMed and may not be about the study. The revision note shows Revision: v3.3.1 replacing v3.2.0.SummaryDifference0.1%

- Check29 days agoChange DetectedRemoval of a general government funding status notice at the top of the page. The core study information, eligibility criteria, and trial details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check43 days agoChange DetectedNo significant additions or deletions affecting core content were detected on the Study Details page. The page content continues to present the trial title, conditions, eligibility criteria, design, and outcome measures as before.SummaryDifference0.4%

- Check71 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center, and a version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference3%

- Check79 days agoChange DetectedUpdated the page from revision v3.0.2 to v3.1.0, signaling a new release version.SummaryDifference0.1%

Stay in the know with updates to PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PI3Kinase Inhibition and Nivolumab in Solid Tumors Clinical Trial page.